Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments. Conducted entirely at the University of Colorado Anschutz, this research has advanced from the laboratory to a Phase 1 clinical trial on the campus.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
A Denver food and cannabis investigator became suspicious of PolkaDot-branded chocolate bars sitting next to convenience store energy shots and nicotine pouches in January 2026. Click here to view original post Click Here to Publish/Feature […]
For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their […]
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster presentations at the Association for […]
Copyright © 2026 Biotech Networks
